Nîmes, France, March 10, 2020 (7:45 a.m. CET) – Advicenne (Euronext Paris & Brussels: ADVIC – FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare kidney diseases, today announced that it has made its lead drug candidate, ADV7103, available for use within the framework of the Temporary Authorization for Use (TAU) scheme established by France’s National Agency of Medicine and Health Products Safety (Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM)).